Clinical Trial Update: Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating REOLYSIN in combination with paclitaxel and carboplatin for non-small cell lung cancer with KRAS or EGFR activation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• REOLYSIN (pelareorep)

Snippet

Sponsor: Oncolytics Biotech | Conditions: Carcinoma, Non-small Cell Lung | Phase 2 | Status: COMPLETED